EUVIMEDEUVIMED entdecken
Open Access

Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors

Chiho Kim iD, Xu-Dong Wang iD, Zhengshuai Liu iD, Jianwei Hao iD, Shuai Wang iD, Peng Li iD, Zhenzhen Zi iD, Qing Ding, Seoyeon Jang iD, Jiwoong Kim iD, Yikai Luo iD, Kenneth E Huffman und 7 weitere

Science Advances · 19.01.2024 · 10 (3)

DOI: 10.1126/sciadv.adh2579 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 19.01.2024. Verfasst von Chiho Kim und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although BRCA1/2 mutations are not commonly found in small cell lung cancer (SCLC), a substantial fraction of SCLC shows clinically relevant response to PARP inhibitors (PARPis). However, the underlying mechanism(s) of PARPi sensitivity in SCLC is poorly understood. We performed quantitative proteomic analyses and identified proteomic changes that signify PARPi responses in SCLC cells. We found that the vulnerability of SCLC to PARPi could be explained by the degradation of lineage-specific oncoproteins (e.g., ASCL1). PARPi-induced activation of the E3 ligase HUWE1 mediated the ubiquitin-proteasome system (UPS)–dependent ASCL1 degradation. Although PARPi induced a general DNA damage response in SCLC cells, this signal generated a cell-specific response in ASCL1 degradation, leading to the identification of HUWE1 expression as a predictive biomarker for PARPi. Combining PARPi with agents targeting these pathways markedly improved therapeutic response in SCLC. The degradation of lineage-specific oncoproteins therefore represents a previously unidentified mechanism for PARPi efficacy in SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsHumansBRCA1 ProteinPoly(ADP-ribose) Polymerase InhibitorsProteomicsBRCA2 ProteinOncogene ProteinsCell Line, TumorTumor Suppressor ProteinsUbiquitin-Protein Ligases

Substanzen

BRCA1 protein, humanBRCA1 ProteinPoly(ADP-ribose) Polymerase InhibitorsBRCA2 protein, humanBRCA2 ProteinOncogene ProteinsHUWE1 protein, humanTumor Suppressor ProteinsUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Department of Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Quantitative Biomedical Research Center, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Hamon Center for Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, Departments of Internal Medicine and Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

ORCID-Profile: Chiho Kim, Xu-Dong Wang, Zhengshuai Liu, Jianwei Hao, Shuai Wang, Peng Li, Zhenzhen Zi, Seoyeon Jang, Jiwoong Kim, Yikai Luo, Sofia Del Rio, Han Liang, Benjamin J Drapkin, John D Minna, Yonghao Yu

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Kim, C., Wang, X. D., Liu, Z., Hao, J., Wang, S., Li, P., Zi, Z., Ding, Q., Jang, S., Kim, J., Luo, Y., Huffman, K. E., Pal Choudhuri, S., Del Rio, S., Cai, L., Liang, H., Drapkin, B. J., Minna, J. D., & Yu, Y. (2024). Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Science Advances, 10(3). https://doi.org/10.1126/sciadv.adh2579

Vancouver

Kim C, Wang XD, Liu Z, Hao J, Wang S, Li P, et al. Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors. Science Advances. 2024;10(3). doi:10.1126/sciadv.adh2579

BibTeX
@article{Kim2024,
  author = {Kim, Chiho and Wang, Xu-Dong and Liu, Zhengshuai and Hao, Jianwei and Wang, Shuai and Li, Peng and Zi, Zhenzhen and Ding, Qing and Jang, Seoyeon and Kim, Jiwoong and Luo, Yikai and Huffman, Kenneth E and Pal Choudhuri, Shreoshi and Del Rio, Sofia and Cai, Ling and Liang, Han and Drapkin, Benjamin J and Minna, John D and Yu, Yonghao},
  title = {Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {3},
  doi = {10.1126/sciadv.adh2579}
}
Kostenlos starten →